

**Performance in Initiating HRA Approved Studies - Q3 2019/20**

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Source for delay correspond to:
14/NE/1180	145170	Effectiveness of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome.	11/01/2018	31/01/2019	21/03/2017	17/05/2019	08/05/2019	06/06/2019	10/06/2019	
19/NW/0001	253853	IDL-2965 ? A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	26/02/2019	26/02/2019						
19/EE/0104	255651	A randomised controlled trial of high-flow nasal oxygen (HFNO) vs. standard oxygen therapy in patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) under conscious sedation.	22/11/2018	15/01/2019	28/03/2019	18/04/2019	08/05/2019	08/05/2019	05/06/2019	
19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	14/02/2019	13/03/2019	17/06/2019	13/08/2019	14/08/2019	14/08/2019		
19/NI/0110	260538	EluNIR Ridaforolimus Eluting Coronary Stent System in patients at high bleeding risk (HBR)? EluNIR HBR study	22/05/2019	12/06/2019	19/07/2019	01/12/2019	03/12/2019	03/12/2019		
18/LO/1492	248861	A Prospective Randomised CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplAntation with and without DeFibrillation Testing	21/03/2019	02/04/2019	12/11/2018	29/07/2019	01/08/2019	01/08/2019	22/08/2019	
19/EE/0237	266273	Papland : Risk Stratification in Cardiac Sarcoidosis	11/01/2019	08/05/2019	29/07/2019	12/09/2019	12/09/2019	01/10/2019		
19/LO/0343	255538	The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization	29/05/2019	08/07/2019	12/08/2019	20/11/2019	21/11/2019	21/11/2019		
19/EE/0091	256412	An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients	09/05/2018	26/07/2019	20/05/2019	10/09/2019	13/09/2019			
19/LO/0576	253302	A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 For the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery	29/08/2018	23/04/2019	07/10/2019	25/11/2019	05/11/2019			
19/NI/0162	260363	Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study.	20/02/2019	27/08/2019	27/09/2019	18/11/2019	19/11/2019	19/11/2019		
18/ES/0147	252929	A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis	19/02/2019	03/05/2019	21/03/2019	13/11/2019	20/11/2019	26/11/2019		
19/NW/0482	269475	A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del	23/05/2019	23/09/2019	27/09/2019	15/10/2019	21/10/2019	21/10/2019		
19/LO/1318	268820	A study to evaluate the effectiveness and safety of VX 445/Tezacaftor/Ivacaftor in people with Cystic Fibrosis who are heterozygous for the F508del mutation and a gating or residual function mutation	10/05/2019	08/08/2019	29/10/2019	22/11/2019	28/11/2019	28/11/2019		
19/YH/0301	268446	A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222 in Cystic Fibrosis subjects who are homozygous for the F508del mutation.	12/02/2019	30/09/2019	31/10/2019	16/12/2019	20/12/2019	03/01/2020		